MX2013015146A - Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. - Google Patents

Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.

Info

Publication number
MX2013015146A
MX2013015146A MX2013015146A MX2013015146A MX2013015146A MX 2013015146 A MX2013015146 A MX 2013015146A MX 2013015146 A MX2013015146 A MX 2013015146A MX 2013015146 A MX2013015146 A MX 2013015146A MX 2013015146 A MX2013015146 A MX 2013015146A
Authority
MX
Mexico
Prior art keywords
treatment
cell carcinoma
renal cell
survival
predictive biomarker
Prior art date
Application number
MX2013015146A
Other languages
English (en)
Other versions
MX358726B (es
Inventor
Abraham Antonio Anderson
David M Weinreich
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2013015146A publication Critical patent/MX2013015146A/es
Publication of MX358726B publication Critical patent/MX358726B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen métodos y composiciones para predecir y tratar el beneficio clínico de paciente con carcinoma de células renales humanas previo de su tratamiento con un inhibidor de VEGFR y un inhibidor de Ang2.
MX2013015146A 2011-06-29 2012-06-28 Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. MX358726B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502686P 2011-06-29 2011-06-29
PCT/US2012/044673 WO2013003606A1 (en) 2011-06-29 2012-06-28 Predictive biomarker of survival in the treatment of renal cell carcinoma

Publications (2)

Publication Number Publication Date
MX2013015146A true MX2013015146A (es) 2014-03-27
MX358726B MX358726B (es) 2018-09-03

Family

ID=46545468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015146A MX358726B (es) 2011-06-29 2012-06-28 Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.

Country Status (7)

Country Link
US (1) US9151761B2 (es)
EP (1) EP2726088B1 (es)
JP (1) JP6069312B2 (es)
AU (1) AU2012275346B2 (es)
CA (1) CA2840212A1 (es)
MX (1) MX358726B (es)
WO (1) WO2013003606A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204516B1 (en) 2014-10-06 2023-04-26 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MX2017005642A (es) * 2014-11-10 2017-07-24 Hoffmann La Roche Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
CA2963175A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
WO2016075034A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
US20190004048A1 (en) * 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
WO2017110764A1 (ja) * 2015-12-24 2017-06-29 公益財団法人がん研究会 マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー
MX2018009112A (es) * 2016-01-25 2018-08-28 Sanofi Sa Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5871723A (en) 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
KR101371773B1 (ko) * 2005-12-15 2014-03-07 아스트라제네카 아베 암 치료를 위한, 안지오포이에틴-2 길항자와 ｖｅｇｆ-ａ,ｋｄｒ 및/또는 ｆｌｔ1 길항자의 조합물
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
JP4897050B2 (ja) 2006-11-10 2012-03-14 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管形成化合物
EP2132572A4 (en) * 2007-03-20 2010-04-14 Apocell Inc EVALUATION OF RTK TARGET MEDICINES
JP5699075B2 (ja) * 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ

Also Published As

Publication number Publication date
US20140348824A1 (en) 2014-11-27
EP2726088B1 (en) 2019-01-02
US9151761B2 (en) 2015-10-06
CA2840212A1 (en) 2013-01-03
AU2012275346A1 (en) 2013-12-19
AU2012275346B2 (en) 2016-03-17
WO2013003606A1 (en) 2013-01-03
JP6069312B2 (ja) 2017-02-01
EP2726088A1 (en) 2014-05-07
MX358726B (es) 2018-09-03
JP2014521070A (ja) 2014-08-25

Similar Documents

Publication Publication Date Title
MX2013015146A (es) Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX2013012167A (es) Estratificaciones a base de bcma y terapia para pacientes con mieloma multiple.
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
ZA201308111B (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
IL231813B (en) Use of preparations containing ATR inhibitors for the treatment of pancreatic cancer and non-small cell lung cancer
PL2544680T3 (pl) Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego
MX2020009704A (es) Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HK1198133A1 (en) Crizotinib for use in the treatment of cancer
ZA201503054B (en) Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
MX2019009539A (es) Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b).
MX358254B (es) Métodos para el tratamiento de cáncer de mama.
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
IN2014DN06104A (es)
GB201109238D0 (en) Antibodies
MX2015001551A (es) Compuestos y composiciones activadoras de enzima.
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
GB201608839D0 (en) Biomarkers useful for detectionof types, grades and stages of human breast cancer
MX2016002938A (es) Prediccion de la recidiva del cáncer de mama.
EP2710379A4 (en) METHODS OF DETERMINING THE PROBABILITY OF SURVIVAL AND EVALUATION OF THE PROBABILITY OF METASTASES IN CANCER PATIENTS
HK1200355A1 (en) Treatment of red blood cells
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
UA61773U (ru) Способ лечения микроэлементозов у новорожденных детей с задержкой внутриутробного развития

Legal Events

Date Code Title Description
FG Grant or registration